16 results about "Tail vein" patented technology

This utility model relates to a simple experimental mouse fixation and tail vein injection device, including a fixation platform, a transparent isolation cover, and a tail fixation component. The transparent isolation cover is used to cover the experimental mouse on the fixation platform. An isolation cover notch is formed at the edge of the open end of the transparent isolation cover, through which the tail of the experimental mouse protrudes. The tail fixation component is used to fix the protruding tail of the experimental mouse on the fixation platform. This utility model combines experimental mouse fixation, tail fixation, and visual monitoring, achieving a dual improvement in drug administration accuracy and simplified experimental operation. It can be operated by a single person and is suitable for precise drug delivery and real-time image monitoring in small animal experiments, possessing high practical value and promising prospects for widespread application.

The utility model discloses a caudal vein injection device, relates to the technical field of mouse caudal vein injection devices, and aims to solve the problems that the stability of the existing mouse caudal vein injection device, a mounting plate and a transparent fixing barrel are of an integrated structure, but the tail end of a mouse is positioned at the joint of the mounting plate and the transparent fixing barrel during injection; the mouse is easily frightened to excrete in the device during injection, and the part is difficult to clean after injection is completed. A transparent fixing barrel is mounted in the middle of one side of the mounting plate, a plugging mechanism is movably mounted in the transparent fixing barrel, locking hooks are symmetrically and fixedly arranged on the upper portion and the lower portion of the side, close to the mounting plate, of the transparent fixing barrel, and locking hook grooves are symmetrically formed in the mounting plate; the locking hook groove and the locking hook are correspondingly arranged, a sliding groove is formed in the front side of the transparent fixing barrel, a locking bolt groove is formed in the rear side of the transparent fixing barrel, and a mouse tail through groove directly communicated with the edge is formed in the center of one side of the mounting plate.

This utility model discloses an auxiliary device for tail vein injection in medical experimental mice. Relating to the technical field of medical experimental equipment, the device includes a base with a fixing frame installed near the edge of the top. A fixing component is provided on the top of the base, and an observation component is provided on one outer wall of the fixing frame. The fixing component includes a lower fixing plate and an upper fixing plate, with the upper fixing plate positioned above the lower fixing plate. This auxiliary device for tail vein injection in medical experimental mice allows the upper fixing plate to move upward a certain distance by pulling a lever, overcoming the spring's thrust, and completely separating the upper and lower arc-shaped plates. The mouse is then placed on the lower arc-shaped plate. Releasing the lever causes the upper arc-shaped plate to move downward under the spring's thrust, thus securing the mouse and effectively avoiding the problem of mice being difficult to stabilize due to their active and restless nature.

The invention relates to a mitochondrial epilepsy mouse disease model and a construction method thereof, which are applied to mitochondrial epilepsy targeted therapy. The PHP.eB-UL12.5 is injected through caudal veins, blood brain barriers can be effectively permeated, mitochondrial genes of mouse brain tissue are cut, mitochondria of the brain tissue loses functions, an epilepsy mouse model induced by mitochondrial DNA deletion is obtained, and the epilepsy mouse model is high in induction success rate, safe, efficient and good in repeatability.

This invention discloses a method for constructing a mouse model of non-obese NAFLD in humans under normal dietary conditions. The method involves injecting adeno-associated virus (adenovirus) shIDO2-AAV8 into mice via the tail vein to target and silence IDO2 gene expression in the liver, while simultaneously administering a normal diet. The adenovirus shIDO2-AAV8 is obtained by recombining an IDO2-shRNA sequence inserted into an AAV8 vector. This invention, through tail vein injection of adenovirus shIDO2-AAV8 combined with a normal diet, can construct a mouse model simulating non-obese NAFLD in humans. Compared with traditional dietary induction methods and combined induction methods, the dietary conditions are consistent with daily human intake, more closely reflecting the actual pathological situation in humans, and more closely reproducing the pathogenesis environment and physical state of non-obese NAFLD in humans, making the model more clinically valuable.

The invention belongs to the technical field of medicines, and particularly relates to application of CD47 as a target spot in treatment of heat stroke. The invention provides application of CD47 in preparation of a medicine or a medicine composition for treating heat stroke. The CD47 is used as a heat stroke treatment target for the first time, and a remarkable treatment effect is achieved. In a heat stroke mouse model, the function damage of multiple organs such as lung, kidney and the like caused by heat stroke can be relieved by injecting the CD47 monoclonal antibody into the caudal vein, the survival rate of the heat stroke mouse is increased, and the survival rate can be increased to about 80% by applying the CD47 monoclonal antibody under the dosage of 10 mg / kg. Therefore, the CD47 can be used as a therapeutic target for preparing the medicine for treating the heat stroke.

The application relates to a method for establishing a systemic amyloidosis model and application, a systemic amyloidosis model is established by injecting amyloidosis lysozyme into the tail vein of a mouse to induce amyloidosis of the mouse tissue, the systemic amyloidosis model obtained can simulate the pathological state of systemic amyloidosis in the body, is used for activity screening of amyloidosis prevention and treatment drugs, and has a good application prospect in the treatment and prevention of amyloidosis.

The invention particularly relates to application of myrobalan tannic acid in preparation of a medicine for treating respiratory syncytial viruses. The administration dosage of the myrobalan tannic acid ranges from 0.016 mg / kg to 0.05 mg / kg. The myrobalan tannic acid disclosed by the invention has the effects of resisting RSV (Respiratory Syndrome Virus) and relieving inflammation on mice in a tail vein injection manner.

The invention relates to an AAV (adeno-associated virus) virus for knocking down CTH (cytidylcholine) in targeted hepatocytes and application thereof, which adopts an adeno-associated virus vector system driven by a TBG promoter to realize specific CTH gene knocking down of the hepatocytes through caudal vein injection. Experiments prove that the targeted knock-down hepatocyte CTH can significantly improve the liver function index of an OC mouse model, relieve inflammatory response and reverse the fibrosis process. The key regulation and control effect of the CTH gene in the OC process is disclosed for the first time, an ideal preclinical research model is provided for developing a CTH-targeted OC treatment medicine, and the application has important application value in the aspect of improving the prognosis of a patient.

The invention belongs to the technical field of biology, and provides an IgM monoclonal antibody for resisting ox-LDL phagocytosis of macrophages, and the IgM monoclonal antibody is respectively named as 1B4, 2B4, 2H8 and 4D3. The four IgM monoclonal antibodies have a good inhibition effect on foam cells formed by phagocytosis of ox-LDL by macrophages, and the IgM antibodies injected through tail vein can significantly inhibit formation of atherosclerotic plaques in a mouse body, and can be used for prevention and treatment of atherosclerosis and atherosclerotic cardiovascular and cerebrovascular diseases caused by atherosclerosis.

The utility model belongs to the technical field of animal medicine experiment instruments, and discloses a combined type fixing device for experimental rat knee joint injection, which comprises two combined type sleeves, a fixing knob, a clamping groove module, a sliding groove, a bottom supporting plate and two adjusting sliding doors. The fusiform closing opening of the front sleeve can fix the head of a rat, the top of the rear sleeve is provided with a groove, the two sides of the bottom of the rear sleeve are provided with openings, the sliding door is adjusted, the tail and the lower limbs of the rat can be fixed, and the front sleeve and the rear sleeve are combined and separated through a fixing knob. The device is especially suitable for knee joint injection molding of experimental rats with different body types, and is also suitable for experiments such as tail injection and caudal vein blood collection. The experimental rat fixing device is environment-friendly in material, low in price, easy to manufacture and convenient to use, efficiency and safety of rat knee joint injection molding can be improved, and the defects of an existing experimental rat fixing device are overcome.

The invention discloses a mouse model construction method for simulating intravenous injection circulating tumor cells, and belongs to the field of cell model construction. The invention discloses a method for constructing a tail vein injection circulating tumor cell mouse model for simulating lung metastasis of breast cancer. The method comprises the following steps: S1, treating a tumor operation specimen before transplantation; s2, constructing a PDX model mouse; s3, obtaining a circulating tumor cell suspension; s4, transplanting the circulating tumor cell suspension into the renal capsule of the immunodeficient mouse; s5, obtaining a tail intravenous injection circulating tumor cell mouse model for simulating the lung metastasis of the breast cancer; and S6, monitoring, verifying and evaluating the model. The problems that in the prior art, sources of circulating tumor cells are mixed, and deviation exists between the circulating tumor cells and actual conditions in clinic are solved, the goodness of fit between the circulating tumor cells and the clinical metastasis process is greatly improved, the number of metastases can be precisely regulated and controlled, and the reliability of data and the effectiveness of statistical analysis are ensured.

The application relates to the field of biological medicine, and discloses a medicine for relieving autoimmune prostatitis and application thereof, which comprises an active ingredient and a pharmaceutically acceptable sterile phosphate buffer carrier; the active ingredient is live Lactobacillus johnsonii with a number of BNCC135265 or extracellular vesicles of Lactobacillus johnsonii; the final concentration of live bacteria in the medicine is 1x10 8 to 1x10 10 CFU / mL, which is used for preparing a preparation for intragastric administration; the extracellular vesicles contain 1x10 8 to 5x10 9 particles per unit dosage form, which is used for preparing a preparation for tail vein injection administration. By using the live bacteria with the specific number or the extracellular vesicles thereof, intestinal mucosa colonization can be achieved to block endotoxin into blood, or the extracellular vesicles can be enriched in prostate lesions to inhibit a nuclear factor-kappa B inflammatory signaling pathway, reduce synthesis of proinflammatory cytokines and lymphocyte infiltration, and finally realize relief of autoimmune prostatitis.

The present disclosure belongs to the technical field of biological medicine, and relates to an mRNA composition and application thereof, wherein the mRNA composition comprises a lipid nanoparticle and mRNA contained in the interior of the lipid nanoparticle, and the mRNA can express CXCL3. After the mRNA composition of the present disclosure is infused through the tail vein, a large number of monocyte-derived macrophages can be chemotactically infiltrated into the cirrhotic liver of a mouse, and the macrophages can phagocytize fibrosis, thereby significantly reducing the fibrosis level in the liver of the mouse. Experimental results show that the composition has almost no toxicity to normal tissues, has high safety, and shows potential in treating liver fibrosis.

The application discloses a kind of methods for constructing deep vein thrombosis mouse model by regulating Pyk2 gene expression.The method comprises the following steps: constructing knockdown or overexpression vector for Pyk2 gene; by tail vein injection, the vector is introduced into mouse in vivo, the in vivo transient regulation of Pyk2 gene is realized; the inferior vena stenosis method is used to induce deep vein thrombosis; the thrombus macroscopic morphology, wet weight, length and histopathology are detected.The application overcomes the limitation of existing gene knockout model, such as congenital, irreversible and systemic deletion, realizes the targeted, temporary and bidirectional flexible regulation of Pyk2 gene in vascular tissue, and the model has high stability and good repeatability.The model can simulate the pathological state under the same expression level of Pyk2, and is suitable for the screening, evaluation and deep vein thrombosis pathogenesis research of antithrombotic drugs.

The application relates to the field of molecular biology and biomedicine technology, and particularly discloses application of Metrnl as a myocardial infarction first-aid medicine. After a mouse is subjected to myocardial ischemia / reperfusion modeling and then treated by Metrnl protein injection through a tail vein, it is found that the treatment of the Metrnl protein can improve the cardiac function in the first, second and third days after myocardial ischemia / reperfusion, improve the myocardial infarction area in the first day, and improve the mortality of the mouse within 7 days. It is shown that the Metrnl can be used as the myocardial infarction first-aid medicine, and has important significance in the treatment of myocardial infarction diseases.